¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦ ½ÃÀå ¿¹Ãø(2030³â) : Áö¿ªº° ºÐ¼® - À¯Çü, ¹æ¹ý, »ùÇà À¯Çü, °ø±Þ¿ø, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°
Asia Pacific DNA Extraction, Isolation, and Purification Market Forecast to 2030 - Regional Analysis - by Type, Method, Sample Type, Source, Application, and End User
»óǰÄÚµå : 1463680
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 161 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,855,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,263,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,670,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº 2022³â¿¡ 5¾ï 536¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 10¾ï 1,429¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022-2030³âÀÇ CAGRÀº 9.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

À¯ÀüüÇÐ ¿¬±¸°³¹ßÀÇ Áõ°¡°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀ» Ȱ¼ºÈ­

À¯ÀüüÇÐÀº À¯Àüº´ Áø´Ü°ú Ä¡·á¸¦ °³¼±ÇÏ´Â Å« °¡´É¼ºÀ» ³»Æ÷Çϰí ÀÖ½À´Ï´Ù. °Ô³ð DNA ÃßÃâÀº »ý¸í°úÇп¡¼­ °¡Àå ÀϹÝÀûÀÎ ÀýÂ÷ Áß ÇϳªÀÔ´Ï´Ù. °Ô³ð DNA´Â »ý¹°ÀÇ À¯Àü ¹°Áú°ú ¿°»öü ¹°ÁúÀ» ¸ðµÎ Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, »ý¸í À¯Áö¿¡ ÇÊ¿äÇÑ ¸ðµç ÄÄÆ÷³ÍÆ®¸¦ ¾ÏȣȭÇϰí ÀÖ½À´Ï´Ù. ¿°±â¼­¿­ °áÁ¤, ¿°±â¼­¿­ µ¥ÀÌÅÍ Á¶¸³ ¹× ºÐ¼®À» À§ÇÑ ÃÖ÷´Ü ±â¼úÀÇ ÃâÇöÀ¸·Î ÀÇÇÐ ¹× ±âŸ °úÇÐ ºÐ¾ß¿¡¼­ À¯ÀüüÇÐÀÇ Á߿伺ÀÌ ´õ¿í Ä¿Áú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó Á¤ºÎ ¹× ºñÁ¤ºÎ ±â°üÀº °Ô³ð ¿¬±¸¸¦ ÃËÁøÇϱâ À§ÇÑ ±¸»óÀ» ÃëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Áö¿øÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº »ç¶÷µéÀÇ DNA ¿¬±¸¸¦ ÇÙ½É ¾÷¹«·Î ÇÏ´Â ¼¼°è ÃÖ°í ¼öÁØÀÇ °Ô³ð ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃâ, ºÐ¸® ¹× Á¤Á¦ ½ÃÀå °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃâ, ºÐ¸® ¹× Á¤Á¦ ½ÃÀåÀº 2022-2030³â°£ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À§¾ÏÀº Áß±¹¿¡¼­ ¾Ï °ü·Ã »ç¸Á ¿øÀÎ Áß 3À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. WCRF ÀÎÅͳ»¼Å³Î¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ º¸°íµÈ ½Å±Ô À§¾Ï »ç·Ê 109¸¸ °Ç Áß 40% ÀÌ»óÀ» Áß±¹ÀÌ Â÷ÁöÇßÀ¸¸ç, 2020³â Áß±¹ ¾Ï °ü·Ã »ç¸ÁÀÇ 12%¸¦ Â÷ÁöÇßÀ¸¸ç, Áß±¹ÀÇ ¾Ï ¹ßº´·ü(¿¬·É Ç¥ÁØÈ­)Àº 10¸¸ ¸í´ç 203.8¸í, 2020³â ½Å±Ô ¹ßº´ °Ç¼ö´Â 4.4¸íÀ¸·Î Áý°èµÇ¾ú½À´Ï´Ù. ½Å±Ô ȯÀÚ ¼ö´Â 4,546,400¸íÀÔ´Ï´Ù. ÀϺ»Àº Àα¸ ±¸Á¶°¡ ºü¸£°Ô °í·ÉÈ­µÇ°í ÀÖ½À´Ï´Ù. °æÁ¦Çù·Â°³¹ß±â±¸(OECD)¿¡ µû¸£¸é 2060³â±îÁö 60¼¼ ÀÌ»ó °í·ÉÀÚ°¡ ÀϺ» Àüü Àα¸ÀÇ 40%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ÀϺ»ÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡´Â ÷´Ü ÀÇ·á ±â¼ú°ú Áø´Ü¿¡ ´ëÇÑ ¾öû³­ ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺ»Àº ¾Ï ¹ßº´·üÀÌ ³ôÀºµ¥, WCRF ÀÎÅͳ»¼Å³Î¿¡ µû¸£¸é 2020³â ÀϺ»ÀÇ ¾Ï ¹ßº´·üÀº 10¸¸ ¸í´ç 282.9¸íÀ̸ç, °°Àº ÇØ »õ·Î º¸°íµÈ ¾Ï ¹ßº´ °Ç¼ö´Â 101¸¸ 7,282°ÇÀÔ´Ï´Ù. ÃÖ±Ù ¸¹Àº ´ëÇü Á¦¾à»ç ¹× ºñÁ¦¾à»çµéÀÌ Àεµ¿¡¼­ À¯Àüü ¿¬±¸¿¡ ¸¹Àº ½Ã°£°ú ÀÚ±ÝÀ» ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. 'Èñ±Í À¯Àü¼º ÁúȯÀÇ À§ÇèÀÌ ³ôÀº Àεµ ¿øÁÖ¹Î'À̶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ µû¸£¸é Àεµ¿¡´Â 800¸¸ ¸í ÀÌ»óÀÇ Èñ±ÍÁúȯ ȯÀÚ°¡ ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ ¸®½ºÆ®¿¡´Â Ç÷¿ìº´, ÁöÁßÇØºóÇ÷, °â»ó ÀûÇ÷±¸Áõ, ¼Ò¾Æ ¿ø¹ß¼º ¸é¿ª °áÇÌÁõ, ÀÚ°¡ ¸é¿ª Áúȯ, ¸®¼ÒÁ» ÀúÀå Áúȯ(ÆûÆäº´, Hirschsprungº´, Gaucherº´, ³¶Æ÷¼º ¼¶À¯Áõ, Ç÷°üÁ¾ µî), ÀϺΠ±ÙÀÌ¿µ¾çÁõ µîÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ 2023³â À¯·´Àΰ£À¯ÀüÇÐÀú³Î(European Journal of Human Genetics)¿¡ ¹ßÇ¥µÈ ¿¬±¸¿¡ µû¸£¸é 2017-2022³â±îÁö Çѱ¹ÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ Áø´Ü ÇÁ·Î±×·¥(KGDP)¿¡ 1,890¸íÀÇ Èñ±ÍÁúȯ ȯÀÚ°¡ µî·ÏµÇ¾ú½À´Ï´Ù. ÀÌ ¿¬±¸¿¡ µû¸£¸é Èñ±ÍÁúȯÀº ¼Ò¾Æ ¹× û¼Ò³â¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÏ´Â °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. µû¶ó¼­ À¯Àü¼º Áúȯ ¹× °¨¿°¼º Áúȯ Áõ°¡´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃâ, ºÐ¸® ¹× Á¤Á¦ ½ÃÀåÀÇ ¼ºÀå¿¡ À¯¸®ÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀÇ ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº À¯Çü, ¹æ¹ý, »ùÇà À¯Çü, ¼Ò½º, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡¿¡ ÀÇÇØ ±¸ºÐµË´Ï´Ù.

À¯Çüº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº ŰƮ, ±â±â, ½Ã¾àÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå Á¡À¯À²Àº ŰƮ ºÐ¾ß°¡ ÃÖ´ë¿´½À´Ï´Ù.

¹æ¹ýº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº È­ÇÐÀû ¹æ¹ý°ú ¹°¸®Àû ¹æ¹ýÀ¸·Î 2ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå Á¡À¯À²Àº È­ÇÐÀû ¹æ¹ýÀÌ Å®´Ï´Ù. È­ÇÐÀû ¹æ¹ýÀº ÇÑÃþ ´õ Æä³î Ŭ·Î·ÎÆ÷¸§, ½Ç¸®Ä« °Ö, ÇÁ·ÎÅ×À̳ªÁ¦, ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù. ¹°¸®Àû ¹æ¹ýÀº Àڱ⠺ñÁî¿Í Á¾ÀÌ·Î ÇÑÃþ ´õ ¼¼ºÐÈ­µË´Ï´Ù.

»ùÇà À¯Çüº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº Ç÷¾×, ü¾×, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå Á¡À¯À²Àº Ç÷¾× ºÎ¹®ÀÌ ÃÖ´ë¿´½À´Ï´Ù.

°ø±Þ¿øº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº °Ô³ð°ú ¹Ì»ý¹°·Î ±¸ºÐµË´Ï´Ù. °Ô³ð ºÎ¹®Àº 2022³â¿¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ º¸´Ù Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ì»ý¹° ºÎ¹®Àº ÇÑÃþ ´õ ¼¼±Õ°ú ¹ÙÀÌ·¯½º·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿ëµµº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº PCR °Ë»ç, Â÷¼¼´ë ½ÃÄö½Ì, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì ºÎ¹®Àº 2022³â¿¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. PCR °Ë»ç ºÎ¹®Àº ¶ÇÇÑ qPCR, ¸ÖƼÇ÷º½º PCR, 16S PCR, ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº Áø´Ü ¼¾ÅÍ¡¤¿¬±¸¼Ò, Á¦¾à¡¤¹ÙÀÌ¿À Á¦¾àȸ»ç, CRO, ±âŸ·Î ±¸ºÐµË´Ï´Ù. Áø´Ü ¼¾ÅÍ¡¤¿¬±¸¼Ò ºÎ¹®ÀÌ, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

±¹°¡º°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, Çѱ¹ , È£ÁÖ, Àεµ³×½Ã¾Æ, ¸»·¹À̽þÆ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº Áß±¹ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù.

Agilent Technologies»ç, Bio-Rad Laboratories Inc»ç, Danaher Corp»ç, F. Hoffmann-La Roche Ltd»ç, GE HealthCare Technologies Inc»ç, Illumina Inc»ç, Merck KGaA»ç, Qiagen NV»ç, Takara Bio Inc»ç, Thermo Fisher Scientific Inc»ç´Â ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦ ½ÃÀå-ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦5Àå DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

Á¦6Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦ ½ÃÀå- 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø - À¯Çüº°

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå- 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø - ¹æ¹ýº°

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå- 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø - »ùÇà À¯Çüº°

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : °ø±Þ¿øº°

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå- 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø - ¿ëµµº°

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : ±¹°¡º° ºÐ¼®

Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾ç DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå - ¾÷°è »óȲ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Asia Pacific DNA extraction, isolation, and purification market was valued at US$ 505.36 million in 2022 and is expected to reach US$ 1,014.29 million by 2030; it is estimated to grow at a CAGR of 9.1% from 2022 to 2030.

Rising R&D in Genomics Fuels the Asia Pacific DNA Extraction, Isolation, and Purification Market

Genomics holds significant potential for improved diagnostics and treatment of genetic diseases. Genomic DNA extraction is one of the most common procedures in the life sciences. Genomic DNA contains all of an organism's genetic and chromosomal material and encodes all of the components required for life. The emergence of cutting-edge technologies for sequencing, and assembly and analysis of sequenced data is likely to strengthen the importance of genomics in medicine and other branches of science. Thus, government and nongovernment agencies are taking initiatives to boost genomic research. The funding enables researchers to provide world-class genomic healthcare, which involves the study of people's DNA as a core job.

Asia Pacific DNA Extraction, Isolation, and Purification Market Overview

The Asia Pacific DNA extraction, isolation, and purification market is expected to record a highest CAGR during 2022-2030. Gastric cancer is the third leading cause of cancer-related deaths in China. The country accounts for more than 40% of new gastric cancer cases out of 1.09 million new cases reported globally; the disease caused ~12% of cancer-related deaths in China in 2020. According to the WCRF International, China had a significant incidence age-standardized rate of 203.8 cancer cases per 100,000, with 4,546,400 new cases in 2020. Japan has a fast-aging demographic profile. According to the Organization for Economic Co-Operation and Development (OECD), people aged 60 and above are expected to account for ~40% of the total population in Japan by 2060. Therefore, the Japanese healthcare system experiences an enormous demand for advanced medical technologies and diagnostics. Further, the country has a high cancer prevalence. According to the WCRF International, Japan had a significant incidence age-standardized rate of 282.9 cancer cases per 100,000 in 2020, with 1,017,282 new cancer cases reported that year. Recently, many big pharmaceutical and nonpharmaceutical companies have invested much time and money for genomics research in India. According to a study titled "Native Americans at Higher Risk for Rare Genetic Diseases," India could be home to over 8 million people suffering from rare diseases, a collective term used to describe a spectrum of over 5,000 diseases that are usually of genetic origin. The list includes hemophilia, thalassemia, sickle cell disease, and primary immunodeficiency in children; autoimmune diseases; lysosomal storage diseases (such as Pompe disease, Hirschsprung disease, Gaucher disease, cystic fibrosis, and hemangiomas); and certain forms of muscular dystrophy. Moreover, according to a study published in 2023 in the European Journal of Human Genetics, 1,890 patients suffering from rare diseases were enrolled in the Korean Genetic Diagnosis Program for Rare Diseases (KGDP) between 2017 and 2022. This study reported that rare diseases are common in children and adolescents. Therefore, the rising cases of genetic disorders and infectious diseases favor the growth of the DNA extraction, isolation, and purification market in Asia Pacific.

Asia Pacific DNA Extraction, Isolation, and Purification Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific DNA Extraction, Isolation, and Purification Market Segmentation

The Asia Pacific DNA extraction, isolation, and purification market is segmented based on type, method, sample type, source, application, end user, and country.

Based on type, the Asia Pacific DNA extraction, isolation, and purification market is categorized into kits, instrument, and reagent. The kits segment held the largest Asia Pacific DNA extraction, isolation, and purification market share in 2022.

In terms of method, the Asia Pacific DNA extraction, isolation, and purification market is bifurcated into chemical method and physical method. The chemical method segment held a larger Asia Pacific DNA extraction, isolation, and purification market share in 2022. The chemical method is further subsegmented into phenol chloroform, silica gel, proteinase, and others. The physical method is further subsegmented into magnetic bead and paper.

By sample type, the Asia Pacific DNA extraction, isolation, and purification market is segmented into blood, body fluid, and others. The blood segment held the largest Asia Pacific DNA extraction, isolation, and purification market share in 2022.

By source, the Asia Pacific DNA extraction, isolation, and purification market is segmented into genomic and microbial. The genomic segment held a larger Asia Pacific DNA extraction, isolation, and purification market share in 2022. The microbial segment is further subsegmented into bacteria and virus.

Based on application, the Asia Pacific DNA extraction, isolation, and purification market is categorized into PCR test, next generation sequencing, micro array, and others. The next generation sequencing segment held the largest Asia Pacific DNA extraction, isolation, and purification market share in 2022. The PCR test segment is further subsegmented into qPCR, multiplex PCR, 16S PCR, and others.

By end user, the Asia Pacific DNA extraction, isolation, and purification market is segmented into diagnostic center and research laboratories, pharmaceutical and biopharmaceutical companies, CROs, and others. The diagnostic center and research laboratories segment held the largest Asia Pacific DNA extraction, isolation, and purification market share in 2022.

Based on country, the Asia Pacific DNA extraction, isolation, and purification market is categorized into China, Japan, India, South Korea, Australia, Indonesia, Malaysia, and the Rest of Asia Pacific. China dominated the Asia Pacific DNA extraction, isolation, and purification market in 2022.

Agilent Technologies, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc, Illumina Inc, Merck KGaA, Qiagen NV, Takara Bio Inc, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific DNA extraction, isolation, and purification market.

Table Of Contents

Table of Content

1. Introduction

2. Executive Summary

3. Research Methodology

4. Asia Pacific DNA Extraction, Isolation, and Purification Market - Key Industry Dynamics

5. DNA Extraction, Isolation, and Purification Market - Asia Pacific Market Analysis

6. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Type.

7. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Method.

8. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Sample Type

9. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Source.

10. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Application.

11. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by End User

12. Asia Pacific DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - Country Analysis

13. Asia Pacific DNA Extraction, Isolation, and Purification Market-Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â